ClinicalTrials.gg
Active, not recruitingNCT03865992Updated Oct 19, 2026

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

An interventional study of Curcumin and Placebo in Breast Cancer and Joint Pain, sponsored by City of Hope Medical Center. Active, not recruiting at 4 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.

Enrollment
31st of 76
42 · median 36
Started
2019
with 1 other
No phase
33 of 89
4 open now
Primary completion
2027-08
later than 26 of 38 live
Registered
65th of 89
by date

Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 31st largest by enrollment of the 76 interventional ones that give a count, is one of 2 that started in 2019, is one of 33 with no phase, reaches primary completion later than 26 of the 38 other live ones, and was the 65th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Breast Neoplasms by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase I trial studies how well curcumin works in reducing joint pain in patients who are breast cancer survivors and have joint disease caused by treatment with aromatase inhibitors. Curcumin is an ingredient of turmeric, a plant in the ginger family, which is commonly used in curries and South Asian and Middle Eastern cooking, and may decrease joint pain in patients with arthritis from other conditions (such as osteoarthritis and rheumatoid arthritis).

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the feasibility of using Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) scores to detect changes in AI-induced symptoms and well-being in postmenopausal women with breast cancer at 3 months of nanoemulsion curcumin (NEC) vs placebo

SECONDARY OBJECTIVES:

I. To evaluate Disabilities of the Arm, Shoulder and Hand (DASH), Brief Pain Inventory, and Geriatric Assessment as secondary tools for monitoring AI-induced symptoms and well-being II. To evaluate adherence to a regimen of NEC vs placebo by postmenopausal women experiencing joint arthropathy induced by aromatase inhibitor therapy III. To obtain preliminary data regarding function in women with AI induced arthropathy (IA) by monitoring grip strength at 0 and 3 months of NEC versus placebo IV. To conduct exploratory analyses of blood based biomarkers in postmenopausal women with AI-induced arthropathy taking NEC vs placebo.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.

03

Conditions studied

  • Breast Cancer
  • Joint Pain

Keywords

  • Breast cancer
  • curcumin
  • aromatase inhibitor
  • joint pain
  • arthropathy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with confirmed primary invasive adenocarcinoma of the breast, stages I-IIIA
  • Estrogen-receptor positive (ER+) and/or progesterone-receptor positive (PR+) breast cancer
  • Completion of definitive surgery with mastectomy or breast conserving therapy
  • (no menses >= 12 months) or on ovarian suppression in order to take AIs
  • Currently taking an Food and Drug Administration (FDA) approved third-generation aromatase inhibitor (e.g., anastrozole [Arimidex], letrozole [Femara], or exemestane [Aromasin]) for >= 90 days prior to registration with plans to continue for >= 90 days after registration
  • Clinical symptoms of joint pain for at least 3 months prior to study entry that started or increased with AI therapy with Brief Pain Inventory (BPI) Worst Pain score >= 4 (verbal response to BPI question 3 regarding the worst pain in the past 24 hours as 0 "no pain" to 10 "pain as bad as you can imagine")

Exclusion criteria

Exclusion Criteria:

  • Prior =\< 5 years except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ of the breast or adequately treated stage I or II cancer from which the patient is currently in complete remission
  • History of a bleeding tendency or current use of coumadin or other anticoagulants
  • Current or previous history of anemia
  • Current , liver, hematopoietic, cardiac, or renal disease
  • Current viral, bacterial, atypical or fungal infections of any organ system
  • Concurrent use of medications
  • Concurrent use of medications known to inhibit or induce hepatic enzyme CYP 3A4 (e.g. ketoconazole, macrolide antibiotics, barbiturates)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements
  • Bone fracture or surgery of the affected joints, within 180 days of study entry
  • Medical therapy, alternative therapy, or physical therapy for joint pain/stiffness =\< 30 days of study entry
  • Intra-articular =\< 90 days of study entry or oral/intramuscular corticosteroids \< 30 days of entry
  • Use of analgesics (e.g., opiates, tramadol with the exception of nonsteroidal anti-inflammatory drugs [NSAIDs] and acetaminophen) within 14 days prior to registration, or at any time during the 3-month study period
  • Chronic use of any herbal or dietary supplement containing curcumin or curcuminoids =\< 3 months of study entry or any other supplements that might interact with NEC (e.g. St. John's Wort)
  • Known sensitivity or allergy to turmeric spices or curry
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Arm I (nanoemulsion curcumin)

    Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.

    Dietary Supplement: Curcumin · Other: Nanoemulsion · Other: Quality-of-Life Assessment · Behavioral: Questionnaire

  • Placebo comparator
    Arm II (placebo)

    Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.

    Other: Placebo

Interventions

  • Dietary supplementCurcumin

    Given capsules for oral administration

    Also known as: C.I. 75300, C.I. Natural Yellow 3, Diferuloylmethane, Turmeric Yellow, (E,E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, 32982, 458-37-7

  • OtherPlacebo

    Given capsules for oral administration

    Also known as: placebo therapy, PLCB, sham therapy

  • OtherNanoemulsion

    Given nanoemulsion curcumin PO

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment,

  • BehavioralQuestionnaire

    Ancillary studies

    Also known as: Questionnaires

06

What researchers measure

Primary outcomes

  1. Changes in aromatase inhibitor-induced symptoms and overall wellbeing in postmenopausal women on aromatase inhibitor therapy

    The study will assess the feasibility of using the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) to detect changes in aromatase inhibitor (AI)-induced symptoms and well-being in postmenopausal women with breast cancer randomized to 3 months of nanoemulsion curcumin (NEC) versus (vs) placebo capsules.

    Time frame: Up to 3 months

  2. Change in Brief Pain Inventory (BPI) pain score

    The scores obtained from the Disabilities of the Arm, Shoulder and Hand (DASH) and BPI, and FACT-ES assessments will be plotted over time for each arm. The agreement between these instruments will be evaluated using Altman and Bland plot after proper data transformation.

    Time frame: Baseline up to 3 months

Secondary outcomes

  1. Incidence of adverse events

    Adverse events will be characterized using the descriptions and grading scales found in the most recent version of the Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 30 days post study-drug assessment

  2. Change in FACT-ES score

    The scores obtained from the BPI, DASH, and FACT-ES assessments will be plotted over time for each arm. The agreement between these instruments will be evaluated using Altman and Bland plot after proper data transformation

    Time frame: Baseline up to 3 months

  3. Change in DASH score

    The scores obtained from the BPI, DASH, and FACT-ES assessments will be plotted over time for each arm. The agreement between these instruments will be evaluated using Altman and Bland plot after proper data transformation.

    Time frame: Baseline up to 3 months

Other outcomes

  1. Joint symptoms occurrence

    The study will use logistic regression models to compare the occurrence of moderate to severe joint symptoms during the 3 month period between the two study groups, with potential covariates including geriatric assessment (GA), age, body mass index, baseline pain scores (0 month), prior chemotherapy e.g. taxanes, time to menopause/ovarian suppression. Summary statistics will be generated using the data obtained from the T0 and T3 study visits where grip strength dynamometry completed. Temporal as well as other relevant correlations between the data and the validated assessment scores will be determined.

    Time frame: Up to 3 months

  2. Blood based biomarker analysis

    The study will explore the relationship between specific inflammatory blood markers, grip strength, and the joint symptoms evaluated by the patient reported outcome measures. The relationship between plasma curcumin and these measures will also be evaluated. Scatter plots and correlation coefficients (either Pearson or Spearman) will be used to summarize their pair wise relation. The differences between the treatment and placebo in terms of these measures will also be reported using numerical summaries and graphic plots.

    Time frame: Up to 3 months

  3. Adherence rates

    Adherence rates will be examined using pill counts each month and patient recorded daily logs. Plasma curcumin will be compared to daily logs and pill count data as another potential measure of adherence.

    Time frame: Up to 3 months

07

Study locations

4 sites
08

References and documents

Publications

  • Lustberg M, Fan-Havard P, Wong FL, Hill K, Phelps MA, Herrera KW, Tsai NC, Synold T, Feng Y, Kalu C, Sedrak MS, Yee LD. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Res Treat. 2024 May;205(1):61-73. doi: 10.1007/s10549-023-07223-4. Epub 2024 Jan 27. PubMed 38280052 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Aug 2027, 99 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 99 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Mar 2019 → Apr 2019, on Oct 19, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2027, on Sep 28, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2027, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Mar 7, 2019
StartActual
Apr 30, 2019was Mar 2019
Primary completionEst.
Aug 4, 2027was Sep 2026
CompletionEst.
Aug 4, 2027was Sep 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 4, 2019→Apr 30, 2019
Oct 19, 2026
Primary completion
Sep 8, 2026→Aug 4, 2027
Sep 28, 2026
Study completion
Sep 8, 2026→Aug 4, 2027
Sep 28, 2026
Show all 2 updates
  1. Oct 19, 2026
    Start date Mar 4, 2019→Apr 30, 2019
    + 1 other change: verification date
  2. Sep 28, 2026
    Primary completion Sep 8, 2026→Aug 4, 2027
    Study completion Sep 8, 2026→Aug 4, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03865992
Responsible party
Sponsor
First posted
Mar 7, 2019
Start date
Apr 30, 2019
Primary completion
Aug 4, 2027 (estimated)
Completion
Aug 4, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Lisa D Yee, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Curcumin

Start the discussion